Medicines optimisation Sample Clauses
Medicines optimisation. Medicines optimisation is a patient-focused, holistic approach to getting the best outcomes from investment in and use of medicines. It requires an enhanced level of patient-centred professionalism, including partnership in decision making between a clinical professional and a patient. NHS England, ABPI and BGMA commit to working together with other stakeholders effectively to communicate, promote and implement medicines optimisation throughout the NHS to achieve the best outcomes at a local level. healthcare professionals in England, May 2013 defines medicines optimisation and sets out four guiding principles describing medicines optimisation in practice.
Medicines optimisation. All sets of Guidance issued from time to time within the overall Medicines Optimisation Programme are designed to aid clinical decision making and are not intended to outweigh clinical judgement exercised in the interests of the patient. Clinicians retain discretion to prescribe the product which the clinician considers best meets the needs and interests of the patient. The HSE/DOH overall approach to Medicines Optimisation has three main strands:
1. The first involves a pharmacist supported medicines usage review process in primary care.
2. The second strand involves the application of prior authorisation/pre-approval requirements for new medicinal products.
3. The third strand involves a number of systemic interventions on existing medicinal products which can be applied at both primary and secondary care level.
Medicines optimisation. 2.3.1 Medicines Usage Review 46
2.3.2 New Medicinal Products-prior authorisation/approval measures 47
2.3.3 Systemic Interventions on Existing Medicinal Products 47 2.3.4 Oral Nutrition Supplements (ONS) 47 2.3.5 Effective Medicine Management 48
2.4.1 Contract Suspension, Sanction and Termination and Dispute Resolution Procedures 49
2.4.2 Complaints Policy and Procedure 49 2.4.3 Practice Profile 49 2.4.4 Assurance Arrangements 50 2.4.5 Premises Standards 50 2.4.6 Patients with Violent or Abusive Behaviour 50 2.4.7 Reduction of Succession Timeframe for GMS Lists 51 2.4.8 Setting of Fee Rates 51 2.4.9 Framework Agreement 51 2.4.10 Paternity & Maternity Leave 51
2.4.11 Allocation of Funding to Support General Practice in Areas of Deprivation 51 2.4.12 Average Weighted Panel Calculations 51
2.4.13 HSE & IMO On-going Process of Engagement 52 2.4.14 Engagement on Agreement 52 2.4.15 Dispensing Doctors Arrangement 52 2.4.16 Review of Under 6s Contract 52 2.4.17 Assessment & Confirmation Process 53 Appendix A1: Minimum Dataset to be recorded and submitted to ▇▇▇ ▇▇ ▇▇▇▇▇▇▇▇ ▇▇: Personalised Care Plan 60 Appendix A3: QRISK 69 Appendix A4: Chronic Disease Definitions 70 Appendix A5: Categorisation Following Opportunistic Case Finding - Data Return 82 Appendix A6: ICGP-IMO agreed statement 83 Appendix A7: Making Every Contact Count Drop Down Menu’s 85 Appendix B1: Job Description 87 Appendix B2: GP Involvement in CHO Implementation Presentation V0.10 88 Appendix C1: GP Involvement in Community Healthcare services – Network Level Service Planning & Management 96 Appendix C2.1: GP Involvement in Community Healthcare services – Multi-disciplinary Team Work and Clinical Team Meeting 99 Appendix C2.2: Clinical Meeting Guidelines 102